HC
XLRN

Hillman Company’s Acceleron Pharma XLRN Stock Holding History

Hillman Company’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-4,400
Closed -$171K – 13
2014
Q4 		$171K Buy
+4,400
New +$153K 0.11% 15

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Hillman Company's XLRN Position: Q1 2015 in Review

Hillman Company sold out of Acceleron Pharma (XLRN) in Q1 2015, closing a stake of 4,400 shares — an estimated $171K sold.

Hillman Company first reported a position in XLRN in Q4 2014 and held it in 1 quarter. The position peaked at $171K in Q4 2014. 115 funds tracked by Wall St. Rank hold XLRN as of Q1 2015.

  • Hillman Company reported no remaining Acceleron Pharma position as of Q1 2015 after selling out during the quarter.
  • Hillman Company sold 4,400 Acceleron Pharma shares in Q1 2015, an estimated $171K.
  • Hillman Company first reported a position in Acceleron Pharma in Q4 2014 and held it in 1 quarter.
  • Hillman Company's Acceleron Pharma position peaked at $171K in Q4 2014.
  • 115 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2015.

Based on Hillman Company's 13F filing for Q1 2015, filed 21 Apr 2015.